The French company specialising in design and commercialisation of AI-powered medical imaging software, Therapixel has raised €15 million in Series B funding. The new capital will boost its commercial presence in the U.S. The funding will also enable the platform to launch more features for its MammoScreen platform and push further the boundaries of its reading aid for mammography.
The round was led by Crédit Mutuel Innovation and CapHorn and joined by Verve, Sham Innovation Santé and historical investors Omnes, IT-Translation, M-Capital and Région Sud Investissement.
With this new investment, the medtech firm has raised more than €20 million since its inception in 2013. The French platform aims to deliver pertinent information at the right time to healthcare professionals. Its MammoScreen breast cancer screening AI solution is being deployed across large networks of breast cancer screening clinics. It uses a unique score to signal at a glance the level of suspicion of a mammogram. Radiologists can thus, feel more confident in their decision and spend more time on difficult cases that require more attention.
Pierre Fillard, chief scientific and technology officer and founder, Therapixel said: “We will accelerate the launch of a new generation of AI that will allow women to benefit from an earlier detection with less anxiety and radiologists to be assisted in the ever-growing demand for imaging. We will also advance the regulatory and clinical developments that will boost our AI solution for radiologists reading mammography.”
Matthieu Leclerc-Chalvet, CEO, Therapixel said: “These funds will allow us to grow our American team with new sales and support people and to ramp up our commercial activities. With an already strong pipeline, Therapixel is poised for significant growth and will have a decisive impact on breast cancer screening.”
Would you like to write the first comment?Login to post comments